Popular Articles

FDA Confirms E. Coli O157:H7 In Prepackaged Nestlç© Toll House Refrigerated Cookie Dough
Today, the U.S. Food and Drug Administration announced that it has found E. coli O157:H7 (a bacterium that can cause serious food borne illness) in a sample of prepackaged Nestlç© Toll House refrigerated cookie dough currently under recall by the manufacturer and marketer, Nestlç© USA. The contaminated sample was collected at Nestlç©"s facility in Danville, Va. on June 25, 2009.

Discovery Of Relationship Between Napping, Hyperactivity, Depression And Anxiety In Young Children
Napping may have a significant influence on young children"s daytime functioning, according to a research abstract presented on Monday, June 8 at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies.
News of the day
Health Insurance Exchanges Gain Attention
Kaiser Health News reports on health insurance exchanges, a concept now being considered in the context of Congress"s health overhaul proposals. "The seemingly simple idea behind exchanges - one-stop shopping for insurance - masks the cornerstone role they may play in a national overhaul of the health system. President Obama supports the idea, and exchanges are included in most of the health care proposals now before Congress. Done right, proponents say, exchanges could transform how insurance is sold, giving individuals and small businesses improved purchasing power, increasing price competition among insurers and creating standardized benefits. Done poorly, analysts and critics say, exchanges could drive up insurance costs and encourage employers to drop coverage, unraveling the system that insures most working Americans. While it"s still unclear what Congress will do, Senate Democrats have looked closely at Massachusetts. Here"s how it works there: The state established its exchange, called the Health Connector, mainly for the benefit of individuals who aren"t insured by employers. They include the self-employed and the unemployed, two categories of people who traditionally have the most difficulty obtaining policies. Although not required to buy through the exchange, doing so gives them group-purchasing power. Lower-income people are eligible for state subsidies."
Oncology

Diamyd(R) Phase III Study Approved For Younger Patients In The US

Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body"s insulin-producing cells, thereby preserving the body"s own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study. "This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world"s largest diabetes conference, the ADA"s 69th Scientific Sessions, which is currently ongoing in New Orleans." The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011. Diamyd Medical is represented at booth #2431 at the ADA"s 69th Scientific Sessions in New Orleans, USA. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company"s most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson"s disease. The company has currently three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements Diamyd Medical AB (publ)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):